These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 24182636)

  • 1. Psychological distress is not associated with treatment failure in patients with gastroesophageal reflux disease.
    Boltin D; Boaz M; Aizic S; Sperber A; Fass R; Niv Y; Dickman R
    J Psychosom Res; 2013 Nov; 75(5):462-6. PubMed ID: 24182636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics of refractory gastroesophageal reflux disease (GERD) symptoms -is switching proton pump inhibitors based on the patient's CYP2C19 genotype an effective management strategy?
    Takeuchi T; Oota K; Harada S; Edogawa S; Kojima Y; Sanomura M; Sakaguchi M; Hayashi K; Hongoh Y; Itabashi T; Kitae H; Hoshimoto M; Takeuchi N; Higuchi K
    Intern Med; 2015; 54(2):97-105. PubMed ID: 25742999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Comorbid Irritable Bowel Syndrome on Treatment Outcome in Non-Erosive Reflux Disease on Long-Term Proton Pump Inhibitor in Japan.
    Funaki Y; Kaneko H; Kawamura Y; Yoshimine T; Tamura Y; Izawa S; Ebi M; Ogasawara N; Sasaki M; Kasugai K
    Digestion; 2017; 96(1):39-45. PubMed ID: 28641289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of treatment pattern and symptom control in patients with gastroesophageal reflux disease: multihospital questionnaire survey on the current situation in Korea.
    Seo SI; Bang CS; Kang HS; Choi MH; Shin WG; Jang HJ; Kim JB; Baik KH; Kae SH; Kim HY
    Dis Esophagus; 2017 Oct; 30(10):1-8. PubMed ID: 28859382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors affecting response to proton pump inhibitor therapy in patients with gastroesophageal reflux disease: a multicenter prospective observational study.
    Matsuhashi N; Kudo M; Yoshida N; Murakami K; Kato M; Sanuki T; Oshio A; Joh T; Higuchi K; Haruma K; Nakada K
    J Gastroenterol; 2015 Dec; 50(12):1173-83. PubMed ID: 25851931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychological modulation in patients surgically intervened for gastroesophageal reflux disease.
    Lara FJ; Carranque G; Oehling H; Hernández JM; Oliva H
    Dis Esophagus; 2014 Aug; 27(6):538-46. PubMed ID: 23121479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of co-morbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastro-oesophageal reflux disease.
    Nojkov B; Rubenstein JH; Adlis SA; Shaw MJ; Saad R; Rai J; Weinman B; Chey WD
    Aliment Pharmacol Ther; 2008 Mar; 27(6):473-82. PubMed ID: 18194508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sleep disturbances and refractory gastroesophageal reflux disease symptoms in patients receiving once-daily proton pump inhibitors and efficacy of twice-daily rabeprazole treatment.
    Fujiwara Y; Habu Y; Ashida K; Kusano M; Higuchi K; Arakawa T
    Digestion; 2013; 88(3):145-52. PubMed ID: 24008338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for proton pump inhibitor refractoriness in Chinese patients with non-erosive reflux disease.
    Niu XP; Yu BP; Wang YD; Han Z; Liu SF; He CY; Zhang GZ; Wu WC
    World J Gastroenterol; 2013 May; 19(20):3124-9. PubMed ID: 23716993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multimodality evaluation of patients with gastroesophageal reflux disease symptoms who have failed empiric proton pump inhibitor therapy.
    Galindo G; Vassalle J; Marcus SN; Triadafilopoulos G
    Dis Esophagus; 2013 Jul; 26(5):443-50. PubMed ID: 22862422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the degree of duodenogastroesophageal reflux and acid reflux between patients who failed to respond and those who were successfully treated with a proton pump inhibitor once daily.
    Gasiorowska A; Navarro-Rodriguez T; Wendel C; Krupinski E; Perry ZH; Koenig K; Moty B; Powers J; Fass R
    Am J Gastroenterol; 2009 Aug; 104(8):2005-13. PubMed ID: 19491829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Causal effect of anxiety and depression status on the symptoms of gastroesophageal reflux disease and functional dyspepsia during proton pump inhibitor therapy.
    Nakada K; Oshio A; Matsuhashi N; Iwakiri K; Kamiya T; Manabe N; Joh T; Higuchi K; Haruma K
    Esophagus; 2023 Apr; 20(2):309-316. PubMed ID: 36251168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concomitant irritable bowel syndrome is associated with failure of step-down on-demand proton pump inhibitor treatment in patients with gastro-esophageal reflux disease.
    Wu JC; Lai LH; Chow DK; Wong GL; Sung JJ; Chan FK
    Neurogastroenterol Motil; 2011 Feb; 23(2):155-60, e31. PubMed ID: 21087355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical, metabolic, and psychological characteristics in patients with gastroesophageal reflux disease overlap with irritable bowel syndrome.
    Hsu CS; Liu TT; Wen SH; Wang CC; Yi CH; Chen JH; Lei WY; Orr WC; Fabio P; Chen CL
    Eur J Gastroenterol Hepatol; 2015 May; 27(5):516-22. PubMed ID: 25822860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors Associated with Potassium-Competitive Acid Blocker Non-Response in Patients with Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease.
    Okuyama M; Nakahara K; Iwakura N; Hasegawa T; Oyama M; Inoue A; Ishizu H; Satoh H; Fujiwara Y
    Digestion; 2017; 95(4):281-287. PubMed ID: 28501868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy of gastroesophageal reflux disease and functional dyspepsia overlaps with symptoms after usual-dose proton pump inhibitor: Acotiamide plus usual-dose proton pump inhibitor versus double-dose proton pump inhibitor.
    Takeuchi T; Takahashi Y; Kawaguchi S; Ota K; Harada S; Kojima Y; Sakamoto H; Kuramoto T; Kojima K; Sanomura M; Hoshimoto M; Higashino T; Itabashi T; Takada K; Sakaguchi M; Tominaga K; Kusano M; Higuchi K
    J Gastroenterol Hepatol; 2018 Mar; 33(3):623-630. PubMed ID: 28865098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors associated with nonresponse to proton pump inhibitors therapy in patients referred for esophageal pH-impedance monitoring.
    Garros A; Mion F; Marjoux S; Damon H; Roman S
    Dis Esophagus; 2016 Oct; 29(7):787-793. PubMed ID: 25951923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of proton-pump inhibitor treatment on symptoms and quality of life in GERD patients depends on the symptom-reflux association.
    Aanen MC; Weusten BL; Numans ME; de Wit NJ; Samsom M; Smout AJ
    J Clin Gastroenterol; 2008; 42(5):441-7. PubMed ID: 18344896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they?
    de Bortoli N; Martinucci I; Savarino E; Bellini M; Bredenoord AJ; Franchi R; Bertani L; Furnari M; Savarino V; Blandizzi C; Marchi S
    Neurogastroenterol Motil; 2014 Jan; 26(1):28-35. PubMed ID: 23992024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release.
    Fass R; Inadomi J; Han C; Mody R; O'Neil J; Perez MC
    Clin Gastroenterol Hepatol; 2012 Mar; 10(3):247-53. PubMed ID: 22155561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.